ArticleJournal of immunology research2026
Evaluating Drug-Target Complexes in Therapeutic Monoclonal Antibodies Using A4F-MALS: Implications for Drug Development and Clinical Design.
Article in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluating Drug-Target Complexes in Therapeutic Monoclonal Antibodies Using A4F-MALS: Implications for Drug Development and Clinical Design.Journal of immunology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic monoclonal antibodies (mAbs) remain an important segment of the biopharmaceutical industry, delivering highly effective and targeted responses against human diseases. The immune complexes formed between a therapeutic mAb and its target antigens may affect efficacy, clearance (pharmacokinetics), and immunogenicity. As such, immune complexes represent an important biophysical property to characterize during drug product screening and development. In this study, we leverage asymmetric flow field-flow fractionation coupled with multiangle light scattering (A4F-MALS) to evaluate the size distribution of complexes formed between a panel of therapeutic mAbs directed against a common target antigen. The inclusion of this analysis enables important insights that can guide the screening of therapeutic candidates during lead candidate assessments, as well as risk mitigation to help better inform clinical design strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.